
Logo Althera
Partnership leverages Tabuk’s extensive regional leadership to broaden access to Althera’s innovative Type 2 Diabetes combination therapy
We are delighted to partner with a true leader across the region. This agreement is a significant step in our mission to make innovative, high-value therapies accessible to patients globally.”— Sanjeev Agarwal, Althera’s CEO
DUBLIN, DUBLIN, IRELAND, December 3, 2025 /EINPresswire.com/ -- Althera Laboratories Limited, a global pharmaceutical company focused on developing value-added cardiovascular and metabolic medicines, and Tabuk Pharmaceuticals, a leading pharmaceutical company in the Middle East and Africa (MENA), today announced a strategic licensing and supply agreement.
The agreement grants Tabuk Pharmaceuticals rights to register and commercialize Althera’s